SAN FRANCISCO, Oct. 28, 2016 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced that it will host an
investor and analyst event at the upcoming Society for
Immunotherapy of Cancer (SITC) 2016 Annual Meeting in National
Harbor, Maryland. The event will be held on November 9, 2016, at 2:30
pm Eastern time and will include a presentation and
discussion of new clinical data from the Phase 1 dose-escalation
(first-in-human) trial of NKTR-214, the Company's
immuno-stimulatory CD122-biased agonist. Presenters
will include Dr. Adi Diab of MD
Anderson Cancer Center and Dr. Mario
Sznol of Yale Cancer Center.
Investors and analysts are invited to listen to a live audio
webcast of the presentation at
http://edge.media-server.com/m/p/8z2ryzkk or by dialing (877)
881-2183 or (970) 315-0453 and using code 9534148. The event will
also be available for replay for two weeks on the company's
website, www.nektar.com.
For those interested in attending this event in person, please
contact jsievers@nektar.com. RSVP space is limited.
About Nektar
Nektar Therapeutics has a robust R&D pipeline and
portfolio of approved partnered medicines in oncology, pain,
immunology and other therapeutic areas. In the area of
oncology, Nektar is developing NKTR-214, an
immuno-stimulatory CD122-biased agonist, that is in Phase 1/2
clinical development for patients with solid tumors. ONZEALD™
(etirinotecan pegol), a long-acting topoisomerase I inhibitor, is
being developed for patients with advanced breast cancer and brain
metastases and is partnered with Daiichi Sankyo in Europe. In
the area of pain, Nektar has an exclusive worldwide
license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. and Japan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and
Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies. ADYNOVATE™ is a
trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements which
can be identified by words such as: "anticipate," "intend," "plan,"
"expect," "believe," "should," "may," "will" and similar references
to future periods. Examples of forward-looking statements include,
among others, statements we make regarding the therapeutic
potential of NKTR-214. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) NKTR-214 is in early-stage
clinical development and there are substantial risks that can
unexpectedly occur for numerous reasons including negative safety
and efficacy findings in the ongoing Phase 1 clinical study
notwithstanding positive findings in preclinical and clinical
studies; (ii) our drug candidates are in various stages of clinical
development and the risk of failure is high and can unexpectedly
occur at any stage prior to regulatory approval for numerous
reasons including negative safety and efficacy findings even after
positive findings in previous preclinical and clinical studies;
(iii) the timing of the commencement or end of clinical trials and
the availability of clinical data may be delayed or
unsuccessful due to regulatory delays, slower than anticipated
patient enrollment, manufacturing challenges, changing standards of
care, evolving regulatory requirements, clinical trial design,
clinical outcomes, competitive factors, or delay or failure in
ultimately obtaining regulatory approval in one or more important
markets; (iv) scientific discovery of new medical breakthroughs is
an inherently uncertain process and the future success of applying
our technology platform to potential new drug candidates (such
NKTR-214) is therefore highly uncertain and unpredictable and one
or more research and development programs could fail; (v) patents
may not issue from our patent applications for our drug candidates
including NKTR-214, patents that have issued may not be
enforceable, or additional intellectual property licenses from
third parties may be required; and (vi) certain other important
risks and uncertainties set forth in our Quarterly Report on Form
10-Q filed with the Securities and Exchange
Commission on August 4, 2016. Any forward-looking
statement made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
Jodi Sievers of Nektar
Therapeutics
415-482-5593
For Media:
Dan Budwick of Pure Communications,
Inc.
973-271-6085
dan@purecommunicationsinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-hold-investor--analyst-event-at-2016-society-for-immunotherapy-of-cancer-annual-meeting-300353358.html
SOURCE Nektar Therapeutics